Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 5/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24375001 | 0.89 | ATM (0.33) | HCRTR2DPP4 | |
| SCHEMBL18513346 | 0.89 | ATM (0.33) | HCRTR2DPP4 | |
| SCHEMBL18513313 | 0.86 | HCRTR2 (0.35) | HCRTR2 | |
| SCHEMBL23710651 | 0.86 | HCRTR2 (0.35) | HCRTR2 | |
| SCHEMBL24098413 | 0.85 | HCRTR2 (0.31) | HCRTR2DPP4 | |
| SCHEMBL22996017 | 0.83 | MMP2 (0.33) | HCRTR2DPP4 | |
| SCHEMBL25492845 | 0.83 | MMP2 (0.33) | HCRTR2DPP4 | |
| SCHEMBL22372628 | 0.80 | — | — | |
| SCHEMBL20016497 | 0.80 | HCRTR2 (0.31) | HCRTR2 | |
| SCHEMBL23790886 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | IONIS PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | APOB, APOL1, LDLR | HCRTR2 3168/4885DPP4 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.